M&A M&A
Undone: Aurobindo Pharma's Rs.420-Cr deal with Cronus cancelled
Aurobindo Pharma's INR 420 crore deal to acquire 51% stake in fellow Hyderabad-based Cronus Pharma Specialities has been cancelled.
More in M&A
- Gas utility GAIL explores stake acquisition in LNG projects in US
- Healthium, Romsons in race to acquire medical devices seller BL Lifesciences
- Agri-trader NHC Foods to acquire 75% stake in Singapore’s DNR Ventures for $5.5 M
- FMCG co. Marico buys addnl 24% stake in Satiya Nutraceuticals for Rs.1,012-Cr